Bimekizumab for adult-onset pityriasis rubra pilaris (PRP)
Treatments studied
Part of Skin clinical trials.
This trial tests a new drug, bimekizumab, for people with PRP, a rare skin condition. It may help reduce skin redness, scaling, and itching.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of PRP from a skin doctor or skin biopsy.
- You have moderate to severe skin plaques covering at least 10% of your body.
- You are generally healthy based on your medical history.
- You are willing to follow the study schedule and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether giving bimekizumab in different ways is safe and how it moves through the body over time. It is for adults with active psoriatic arthritis or axial spondyloarthritis who may benefit from bimekizumab treatment.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
This trial tests if the drug bimekizumab can slow down chronic inflammation in people with early plaque psoriasis. It's for adults 18-44 with mild psoriasis who haven't used topical treatments recently.
This trial tests a drug called bimekizumab in children and teens with specific types of juvenile arthritis (enthesitis-related arthritis or psoriatic arthritis). It aims to see how the drug works in the body and if it's safe. This may help those who haven't gotten enough relief from standard anti-inflammatory medicines.
This study tests whether the drug bimekizumab can help heal ulcers caused by a rare skin condition called pyoderma gangrenosum (PG). If you have PG and are already taking prednisone, this trial may offer a new treatment option.
This study measures how much bimekizumab (Bimzelx) gets into breast milk. It helps us understand if the medicine is safe for breastfeeding babies whose mothers take this drug.
Hear when a new Pityriasis Rubra Pilaris trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.